Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial

PK Judge(Unknown), A. Q. Adeleke(Universiti Malaysia Pahang Al-Sultan Abdullah), SJ Hauske(Boehringer Ingelheim (Germany)), Karl Wallendszus, Julie Green, Natalie Staplin(University of Oxford), David Z.I. Cherney(University Health Network), Colin Baigent(University of Oxford), Jonathan Emberson(University of Oxford), Christoph Wanner(Universitätsklinikum Würzburg), Masaomi Nangaku(The University of Tokyo), David Preiss(Medical Research Council), Takashi Kadowaki(Toranomon Hospital), Adeera Levin(University of British Columbia), Katherine R. Tuttle(Providence Regional Medical Center Everett), Xavier Rosselló(Spanish National Centre for Cardiovascular Research), Dominik Steubl(Boehringer Ingelheim (Germany)), Nader G. Abraham(Duke University), Rajat Deo, WG Herrington(Boehringer Ingelheim (Germany)), Emily Sammons(University of Oxford), Rizna Abdul Cader(Boehringer Ingelheim (Germany)), MZ Abdul Wahab, AK Cheung, Talal Abdulsamad, Martin Landray(Gentofte Hospital), Roberto Pontremoli(Ospedale Policlinico San Martino), Daisy Massey, Susanne Brenner, Shinichi Goto, Aldo P. Maggioni(Health Care Foundation), Richard Haynes, Riaz Rahman, S Abat, P Achiri, J Li(Shandong University), Wenjun Liu(Liaoning University of Traditional Chinese Medicine), Zhihong Liu(Chinese Academy of Sciences), NK Abdullah, Dandan Zhu, MI Abdul Hafidz, AJ Roddick, LS Hooi, W. Grant Stevens, Sarah Acheampong, KJ Mayne, SYA Ng, Masanori Abe(Japanese Society for Dialysis Therapy), JA Acosta, Michael Hill(University of Ottawa)
The Lancet Diabetes & Endocrinology
December 4, 2023
Cited by 107


Related Papers